Ubs Asset Management Americas Inc Tg Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $477 Billion
  • Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 409,393 shares of TGTX stock, worth $15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
409,393
Previous 287,059 42.62%
Holding current value
$15 Million
Previous $11.3 Million 30.18%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$33.37 - $45.51 $4.08 Million - $5.57 Million
122,334 Added 42.62%
409,393 $14.7 Million
Q1 2025

May 19, 2025
BUY
$27.67 - $42.99 $406,444 - $631,480
14,689 Added 5.39%
287,059 $11.3 Million
Q4 2024

Feb 14, 2025
SELL
$21.31 - $35.09 $459,379 - $756,435
-21,557 Reduced 7.33%
272,370 $8.2 Million
Q3 2024

Nov 14, 2024
SELL
$17.21 - $25.28 $480,967 - $706,500
-27,947 Reduced 8.68%
293,927 $6.87 Million
Q2 2024

Aug 13, 2024
BUY
$13.32 - $19.19 $2.13 Million - $3.07 Million
159,947 Added 98.78%
321,874 $5.73 Million
Q3 2023

Nov 13, 2023
BUY
$8.36 - $26.5 $232,449 - $736,832
27,805 Added 20.73%
161,927 $1.35 Million
Q1 2023

May 15, 2023
SELL
$10.23 - $19.34 $223,535 - $422,598
-21,851 Reduced 14.01%
134,122 $2.02 Million
Q4 2022

Feb 14, 2023
BUY
$5.01 - $11.83 $72,113 - $170,281
14,394 Added 10.17%
155,973 $1.85 Million
Q3 2022

Nov 14, 2022
SELL
$4.57 - $8.4 $25,016 - $45,981
-5,474 Reduced 3.72%
141,579 $838,000
Q2 2022

Aug 12, 2022
BUY
$3.74 - $10.66 $4,383 - $12,493
1,172 Added 0.8%
147,053 $624,000
Q1 2022

May 16, 2022
BUY
$7.81 - $20.45 $232,245 - $608,121
29,737 Added 25.6%
145,881 $1.39 Million
Q4 2021

Feb 14, 2022
SELL
$15.2 - $35.51 $44,596 - $104,186
-2,934 Reduced 2.46%
116,144 $2.21 Million
Q3 2021

Nov 15, 2021
BUY
$21.78 - $40.45 $146,688 - $272,430
6,735 Added 6.0%
119,078 $3.96 Million
Q2 2021

Aug 16, 2021
BUY
$32.5 - $48.96 $291,070 - $438,485
8,956 Added 8.66%
112,343 $4.36 Million
Q1 2021

May 14, 2021
SELL
$41.61 - $54.3 $19.4 Million - $25.4 Million
-467,290 Reduced 81.88%
103,387 $4.98 Million
Q4 2020

Mar 01, 2021
SELL
$25.27 - $54.9 $1.83 Million - $3.97 Million
-72,256 Reduced 11.24%
570,677 $29.7 Million
Q3 2020

Nov 13, 2020
SELL
$18.49 - $27.24 $625,313 - $921,229
-33,819 Reduced 5.0%
642,933 $17.2 Million
Q2 2020

Aug 14, 2020
BUY
$8.9 - $21.84 $129,548 - $317,903
14,556 Added 2.2%
676,752 $13.2 Million
Q1 2020

May 15, 2020
SELL
$7.14 - $15.99 $496,237 - $1.11 Million
-69,501 Reduced 9.5%
662,196 $6.52 Million
Q4 2019

Feb 14, 2020
BUY
$5.1 - $11.2 $420,999 - $924,548
82,549 Added 12.72%
731,697 $8.12 Million
Q3 2019

Nov 14, 2019
BUY
$5.38 - $8.99 $213,984 - $357,568
39,774 Added 6.53%
649,148 $3.65 Million
Q2 2019

Aug 15, 2019
BUY
$6.27 - $8.65 $93,893 - $129,533
14,975 Added 2.52%
609,374 $0
Q1 2019

May 14, 2019
SELL
$4.02 - $8.04 $256,351 - $512,702
-63,769 Reduced 9.69%
594,399 $0
Q4 2018

Feb 13, 2019
SELL
$3.44 - $5.76 $114,524 - $191,761
-33,292 Reduced 4.81%
658,168 $2.7 Million
Q3 2018

Nov 14, 2018
SELL
$5.15 - $14.0 $27,459 - $74,648
-5,332 Reduced 0.77%
691,460 $0
Q2 2018

Aug 14, 2018
SELL
$12.5 - $15.0 $3.18 Million - $3.81 Million
-254,142 Reduced 26.73%
696,792 $0
Q1 2018

May 14, 2018
SELL
$8.7 - $16.8 $1.04 Million - $2.01 Million
-119,681 Reduced 11.18%
950,934 $0
Q4 2017

Feb 09, 2018
SELL
$7.35 - $12.3 $148,991 - $249,333
-20,271 Reduced 1.86%
1,070,615 $0
Q3 2017

Nov 13, 2017
BUY
$10.0 - $12.7 $10.9 Million - $13.9 Million
1,090,886
1,090,886 $0

Others Institutions Holding TGTX

# of Institutions
406
Shares Held
92.4M
Call Options Held
2.28M
Put Options Held
1.78M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.34B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email